Transglutaminase 2 Expression Predicts Progression Free Survival in Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
| Autor: | Sun Min Lim, Byoung Chul Cho, Hyo Sup Shim, Hye Ryun Kim, Soo Youl Kim, Joo Hang Kim, Jae Heon Jeong, Kyung Young Chung, Se Kyu Kim, S. M. Bakhtiar Ul Islam, Jae J. Song |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Lung Neoplasms Tissue transglutaminase medicine.medical_treatment Antineoplastic Agents Drug resistance Adenocarcinoma Disease-Free Survival NF-κB GTP-Binding Proteins Carcinoma Non-Small-Cell Lung Internal medicine medicine Humans Protein Glutamine gamma Glutamyltransferase 2 Oncology & Hematology Progression-free survival Epidermal growth factor receptor Lung cancer Protein Kinase Inhibitors Aged Aged 80 and over Chemotherapy Transglutaminases biology Kinase business.industry NF-kappa B General Medicine Middle Aged medicine.disease ErbB Receptors Transglutaminase 2 Treatment Outcome Endocrinology biology.protein Female Original Article business |
| Zdroj: | Journal of Korean Medical Science |
| ISSN: | 1598-6357 1011-8934 |
| DOI: | 10.3346/jkms.2013.28.7.1005 |
| Popis: | Transglutaminase 2 (TG2), a cross-linking enzyme, is involved in drug resistance and in the constitutive activation of nuclear factor kappa B (NF-κB). We investigated the association of non-small cell lung cancer (NSCLC) treatment efficacy with TG2 and NF-κB expression in 120 patients: 102 with adenocarcinoma and 18 with other histologic types. All patients underwent surgery; 88 received adjuvant chemotherapy, with 28 receiving platinum-based doublet chemotherapy as first-line treatment and 29 receiving epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Patients' TG2 and NF-κB expression values were calculated semiquantitatively. The median TG2 value was 50 (range, 0-300) and the median NF-κB value was 20 (range, 0-240). Disease-free survival did not differ between the low- and high-TG2 groups. Among patients who received palliative platinum-based doublet chemotherapy, progression free survival (PFS) was longer in the low-TG2 group than in the high-TG2 group (11.0 vs. 7.0 months; P=0.330). Among those who received EGFR-TKI therapy, PFS was also longer in the low-TG2 group than in the high-TG 2 group (11.0 vs. 2.0 months; P=0.013). Similarly, in EGFR wild-type patients treated with EGFR-TKI, PFS was longer in patients with low TG2 expression (9.0 vs. 2.0 months; P=0.013). TG2 expression levels can predict PFS in patients with NSCLC treated with EGFR-TKI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|